{"resourceType": "Composition", "id": "399866", "meta": {"profile": ["http://hl7.org/fhir/uv/pharmaceutical-research-protocol/StructureDefinition/m11-research-study-narratives"], "versionId": "2", "lastUpdated": "2025-09-14T18:15:51.793Z"}, "text": {"status": "generated", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Composition IGBJ-Narrative-2.1</b></p><a name=\"IGBJ-Narrative-2.1\"> </a><a name=\"hcIGBJ-Narrative-2.1\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-m11-research-study-narratives.html\">Research Study Narratives</a></p></div><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/uv/pharmaceutical-research-protocol/CodeSystem/narrative-elements-cs b001}\">Protocol narrative</span></p><p><b>date</b>: 2025-06-03 12:46:00+0000</p><p><b>author</b>: <a href=\"Organization-IGBJ-Organization.html\">Organization Eli Lilly Japan K.K</a></p><p><b>title</b>: IGBJ Protocol Narrative 2.1</p></div>"}, "status": "final", "type": {"coding": [{"system": "http://hl7.org/fhir/uv/pharmaceutical-research-protocol/CodeSystem/narrative-elements-cs", "code": "b001", "display": "Protocol narrative"}]}, "subject": [{"reference": "ResearchStudy/399864", "type": "ResearchStudy", "display": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus (399864)"}], "date": "2025-09-14T18:15:51.793Z", "author": [{"reference": "Organization/399869", "type": "Organization", "display": "Eli Lilly Japan K.K (399869)"}], "title": "IGBJ Protocol Narrative 2.1", "url": "https://fevir.net/resources/Composition/399866", "custodian": {"reference": "Organization/118079", "type": "Organization", "display": "Computable Publishing LLC"}, "identifier": [{"type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}], "text": "FEvIR Object Identifier"}, "system": "https://fevir.net/FOI", "value": "399866", "assigner": {"display": "Computable Publishing LLC"}}], "relatesTo": [{"type": "cite-as", "targetMarkdown": "IGBJ Protocol Narrative 2.1 [Database Entry: FHIR Composition Resource]. Contributors: Eli Lilly Japan K.K (399869) [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399866. Revised 2025-09-14. Available at: https://fevir.net/resources/Composition/399866. Computable resource at: https://fevir.net/resources/Composition/399866#json."}], "section": [{"title": "2.1 Purpose of Trial", "code": {"coding": [{"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl", "code": "C218521"}]}, "text": {"status": "additional", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">|1. have had a diagnosis of either:| |a. T1DM based on the World Health Organization (WHO) diagnostic criteria, and have been on the following daily insulin therapy for at least 1 year \u200b i. multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or \u200b ii. continuous subcutaneous insulin infusion (CSII) | |**Or** b. T2DM based on the WHO diagnostic criteria, and have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year \u200b i. insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII \u200b ii. OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine | | tabl title | | ---------- | | row 1 | | row 2 | | row 3 |</div>"}}]}